{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-22-001006","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2022-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.898058+00:00","generated_at":"2026-06-27T00:22:59.255603+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Chemomab reports FY2021 net loss of $12.5M; revises CM-101 clinical program to extend cash runway through end 2023","bullets":["Net loss $12.5M ($0.06 per share) in FY2021 vs $6.0M in FY2020; cash $61.2M at Dec 31, 2021.","Expanding Phase 2 PSC trial with dose-finding cohorts and open-label extension; interim analysis expected H2 2022.","Focusing SSc trial on earlier proof of concept; trial initiation anticipated H2 2022.","Winding down liver fibrosis subcutaneous formulation study; data readout targeted near end of 2022.","Cash runway extended ~6 months to end of 2023; company expects 3-4 data readouts over next 24 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-22-001006","json":"https://secwatch.observer/filing/0001178913-22-001006.json","markdown":"https://secwatch.observer/filing/0001178913-22-001006.md","text":"https://secwatch.observer/filing/0001178913-22-001006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001006/0001178913-22-001006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001006/zk2227450.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:22:59.255603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}